GTx is a company of experienced individuals who are dedicated to developing novel targeted hormonal therapies to provide better medicines for patients.
At GTx, we focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. We are developing selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy.
In addition, we have compounds that selectively target estrogen receptors in preclinical development for fibrotic conditions, such as Idiopathic Pulmonary Fibrosis (IPF).
To further explore treatments targeting diseases caused by abnormal androgen receptor signaling, we have a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.